APLS241220C60000
- 0.05
- 0.000.00%
Apellis Pharmaceuticals Newsroom
RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley
Morgan Stanley Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $31
Neutral Stance on Apellis Pharmaceuticals Amid Competitive Uncertainties and Market Stability
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Apellis Pharmaceuticals Up Nearly 16%, On Pace for Largest Percent Increase Since August 2023 -- Data Talk
Astellas Receives Complete Response Letter From FDA for Izervay SNDA
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
Apellis Pharmaceuticals (APLS) Receives a Buy From Jefferies
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $32
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Apellis Pharmaceuticals: Strategic Advantage and Market Potential Boost With Syfovre's Competitive Edge
Hold Rating on Apellis Pharmaceuticals Amid Regulatory Setbacks and Market Uncertainties
Insider Sellers Might Regret Selling Apellis Pharmaceuticals Shares at a Lower Price Than Current Market Value
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference